Key Highlights

● Cardinal Health shares fell about 0.7% to $244.76, with no company news behind it.

● The drop extended a pullback after the stock climbed about 14% over the prior month.

● Cardinal Health recently extended its drug-distribution agreement with CVS Health through 2032.

● The company reports fiscal first-quarter results on November 5, 2026.

Cardinal Health (NYSE:CAH) shares fell about 0.7% on October 28, 2026, closing at $244.76 on the New York Stock Exchange. No company-specific announcement was identified for the session. The decline extended a pullback from the stock's 52-week high near $259, set earlier in October, and came a week before the company's next scheduled earnings report.

A Pullback After a Strong Run

The shares had climbed sharply into late October, helped by two pieces of news. On October 1, Cardinal Health agreed to extend its pharmaceutical distribution agreements with CVS Health (NYSE:CVS) through June 2032, securing one of its largest customer relationships for several more years. The stock has since given back a portion of that advance as investors positioned ahead of results.

A Major Customer Agreement Extended

Cardinal Health is one of the three large US pharmaceutical wholesalers, alongside McKesson (NYSE:MCK) and Cencora (NYSE:COR). Its largest unit distributes branded, generic, and specialty drugs to pharmacies, hospitals, and physician practices, and accounted for the great majority of the company's fiscal 2026 revenue of $254.2 billion. A smaller Global Medical Products and Distribution segment makes and distributes medical and surgical supplies.

What Cardinal Health Does

For the fiscal year ended June 30, 2026, Cardinal Health reported revenue up 14% and non-GAAP diluted earnings per share up 37% to $11.26. It repurchased $1.4 billion of stock during the year and expanded its buyback authorization. For fiscal 2027, the company guided to non-GAAP earnings per share growth of 13% to 15%.

A High-Volume, Thin-Margin Business Awaits Its Next Print

Drug distribution is a high-volume, thin-margin business, since most of Cardinal Health's revenue is the pass-through cost of the drugs it buys and resells. That structure means small shifts in generic pricing or customer terms can have an outsized effect on reported profit, a dynamic that leaves the stock sensitive to its upcoming results.